 |
|
|
 |
Home
Welcome to the recently named TRIO (Translational Research in Oncology) organization (ex-Cancer International Research Group).
TRIO is a not-for-profit clinical research organization with offices based in Canada, France and Uruguay.
With an international network of 2000 investigators and 450 cancer centers in over 45 different countries, TRIO has conducted a number of new and innovative global studies evaluating systemic therapy for cancer.
TRIO entity comes from the merge of CIRG and TORI the wide group of preclinical researchers at UCLA to become part of an exciting innovative translational research program.
TRIO is developing from proof of concept up to registrational phase III trials in different setting such as breast, ovary, GI….
> Last News :
Publication of the BCIRG 006 study: Adjuvant Trastuzumab in HER2-Positive Breast Cancer, D. Slamon and Others in New England Journal of Medecine 2011 365;1273-1283 October 6
Reprints will be mailed to all Investigators who participated to the trial.
WWolfgang Eiermann, Tadeusz Pienkowski, John Crown, Saeed Sadeghi, Miguel Martin, Arlene Chan, Mansoor Saleh, Sandeep Sehdev, Louise Provencher, Vladimir Semiglazov, Michael Press, Guido Sauter, Mary-Ann Lindsay, Alessandro Riva, Marc Buyse, Philippe Drevot, Henry Taupin, and John R. Mackey.Reprints will be mailed to all Investigators who participated to the trial.
The Translational symposium:
"Hot Topics in Translational Research: Transforming
Cutting-Edge Discoveries to Clinical Practice"
proposed and presented by TRIO Directors
held early June at ASCO and organised by CCO (www.clinicaloptions.com/translational2011) in partnership with TRIO, was a great success. By clicking on each items of the agenda below you will be able to access to each presentations graciously provided by each speaker for your reference. Please save first on your computer to allow quick reading!.
Agenda
Welcome and Introduction
Dennis J. Slamon, MD, PhD Program Chair
Identifying Tumors Expressing Predictive Markers: Lessons Learned From HER2
Dennis J. Slamon, MD, PhD
IGFR: A New Target for Multiple Tumor Types
Gottfried Konecny, MD
Targeting the PI3K Pathway
Carlos L. Arteaga, MD
Panel Discussion
Antireplication Agents: CDK Inhibitors and Telomerase Inhibitors
Richard Finn, MD
Antiangiogenesis: Using Old and New Approaches
John R. Mackey, MD, FRCP(C)
DNA Repair Pathways and PARP Inhibition
Nicholas Turner, MD
Panel Discussion/Concluding Remarks
----------------------------------------------------
-
CIRG-TORI 010 study Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study published inThe Lancet Oncology, Early Online Publication, 22 March 2011]
-
BCIRG 006 Sub-study Alteration of Topoisomerase II-Alpha Gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy" Michael Press et al. published on JCO Vol 29, N°7 March 1 2011.
-
BCIRG 007 article on study results published on JCO vol.29:149-156, 2011.
- BCIRG 001 : 10-year follow-up, final results presented at the San Antonio Breast Cancer Conference on December 10th, 2010.
-
Information on CCO point-of-care resource designed specifically for oncologists, click here for more information
-
3rd analysis of BCIRG 006 presented by Dr Slamon on December 12 at the 2009 SABCS conference (GENERAL SESSION 5 -Exhibit Hall D)
Abstract 62. Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC -> T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC -> TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 StudyClick here to access the official BCIRG 006 Presentation in pdf format (Slides set in jpg format - zipped file)
-
2nd analysis of CIRG/TORI 010 study presented at the 2009 SABCS conference by Dr John Mackey from the Cross cancer Institute , abstract 47 CIRG/TORI 010: First Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel (P) as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC)
Click here to access the official CIRG/TORI 010 Presentation -
Analysis of Fcg Receptor IIa and IIIa Polymorphisms: Correlation with Outcome in Trastuzumab-Treated Her2/neu Amplified Early and Metastatic Breast Cancer Patients (from breast cancer patients treated in the BCIRG-006 study) presented by Dr. Sara Hurvitz from UCLA at 2009 SABCS conference. Abs.64 Click here to access slides presentation
-
SABCS 2008: BCIRG 005 presentation on Efficacy results
For information on new TRIO-CIRG studies please click in the Studies Summary on left side menu.
________________________________________________________
